Pliant Therapeutics, Inc. (PLRX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-67.7%

$0.27

vs $0.84 price

Levered DCF

$0.27

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-6.55

Distress zone

Rating

B-

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.5×	-3.8×	-6.59×	-6.57×	-4.98×	-19.42×	-112.11×	-11.64×
P/B	0.41×	2.62×	2.25×	2.59×	2.43×	2.85×	-1,740.79×	-398.71×
P/S	0×	0×	673.04×	83.86×	63.91×	19.32×	13.27×	0×
EV / EBITDA	-0.4×	-3.83×	-6.39×	-6.58×	-4.59×	-18.76×	-5,693.9×	-9.63×
Gross margin	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%
Operating margin	0.0%	0.0%	-11654.7%	-1313.4%	-1288.1%	-99.6%	-2.2%	0.0%
Net margin	0.0%	0.0%	-10211.1%	-1273.3%	-1284.5%	-99.3%	-1.1%	0.0%
Current ratio	12×	10.91×	17.72×	14.23×	12.44×	25.07×	13.69×	12.14×
Debt / equity	0.16×	0.2×	0.02×	0.05×	0.04×	0×	-1.02×	-0.6×
Interest coverage	-58.65×	-75.52×	-145.34×	-160.81×	0×	-113.78×	-5.7×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-82.4%	-69.2%	-34.1%	-39.4%	-48.9%	-14.7%	145.1%	3432.7%
Return on invested capital	-71.4%	-62.7%	-38.0%	-38.6%	-47.3%	-14.7%	-1.1%	-50.3%
Return on assets	-66.3%	-53.0%	-31.5%	-35.2%	-44.0%	-14.1%	-0.5%	-45.5%
Free cash flow yield	-171.9%	-20.0%	-11.0%	-11.9%	-16.0%	-4.8%	-0.5%	-8.7%
Earnings yield	-199.5%	-26.4%	-15.2%	-15.2%	-20.1%	-5.1%	-0.1%	-8.6%
Enterprise value	$58.5M	$786.3M	$1B	$794.3M	$439.5M	$756.9M	$671.9M	$291.2M
Net debt / EBITDA	0.11×	0.05×	0.33×	0.15×	0.46×	1.26×	723.42×	2×
Cash conversion cycle (days)	-103	0	692	118	119	82	47	-1,412